We are committed to developing new treatment options for mental health conditions and to rigorously evaluating their safety and efficacy through clinical research.
We currently have two drug development programs in the clinical stage.
Psilocybin
Usona is currently studying psilocybin as a potential treatment for major depressive disorder (MDD).
LEARN MORE ABOUT PSILOCYBIN
5-MeO-DMT
Usona has successfully completed all dosing sessions for our first clinical study evaluating 5-MeO-DMT in healthy volunteers. This represents an important milestone in the clinical development of our 5-MeO-DMT program.
LEARN MORE ABOUT 5-MeO-DMT
Psilocybin and 5-MeO-DMT are investigational drugs that have not been approved by the U.S. Food and Drug Administration. Their safety and efficacy have not been established.